Computational pathology, which assesses molecular-level features of diseases directly from tissue images (rather than testing the tissue via methods such as staining or sequencing) is making rapid strides. Read More
Researchers from the Innovation Program of Drug Research on Inflammatory and Immune Diseases at NMPA Key (China) and collaborators aimed to further investigate the impact of Src homology phosphatase 2 (SHP2) on breast cancer-induced bone destruction. Read More
Montis Biosciences BV has released preclinical data on its lead program, MB-0109, in support of its development to treat neuro-autoimmune indications. Read More
Sanaregen Vision Therapeutics Inc. has received FDA clearance to conduct a phase I/II trial of SVT-001, an investigational cell therapy for individuals with familial drusen. Read More
STAT3 promotes cancer cell survival and supports microtubule-mediated mitotic processes, making combined STAT3 inhibition and microtubule targeting a rational strategy to suppress tumor growth and overcome therapy resistance. Read More
Cure Rare Disease has entered into a multiyear partnership with the LGMD2L Foundation to develop a gene replacement therapy for anoctamin 5 (ANO5)-related disease, a rare genetic disorder. Read More
Dice Alpha Inc. has disclosed interleukin-17A (IL-17A) inhibitors designed for use in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis and more. Read More
Researchers from Specally (Wuhan) Life Technology Co. Ltd. have disclosed the discovery and preclinical profile of WWZ-11-098, a non-palbociclib-based, selective cyclin-dependent kinase 6 (CDK6) degrader in models of leukemia. Read More
Rongchang Pharmaceutical (Zibo) Co. Ltd. has synthesized nitrogen-containing fused ring compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes. Read More
CHA University has identified chalcone derivatives acting as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors potentially useful for the treatment of Alzheimer’s disease. Read More
Ono Pharmaceutical Co. Ltd. has entered into an agreement to expand its drug discovery collaboration agreement with Congruence Therapeutics Inc. for the discovery of novel small-molecule modulators against multiple protein targets in the areas of neurology and immunology. Read More
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors for use in the treatment of cancer. Read More
Calidi Biotherapeutics Inc. recently presented data regarding CLD-401 as an immunotherapeutic approach developed using the Redtail gene therapy platform. This platform uses a tumor-specific, replicating enveloped vaccinia virus that expresses a chimeric form of CD55 to allow complement and neutralizing antibody resistance, as well as systemic administration. Read More
